378 related articles for article (PubMed ID: 38339003)
21. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.
Sanlorenzo M; Vujic I; Moy A; Quaglino P; Fierro MT; Gammaitoni L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015; 15(10):1491-500. PubMed ID: 26206099
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
25. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
Trojaniello C; Sparano F; Cioli E; Ascierto PA
Curr Oncol Rep; 2023 Jun; 25(6):623-634. PubMed ID: 36995534
[TBL] [Abstract][Full Text] [Related]
26. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR; Saturno G; Lorigan P; Marais R
Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
[TBL] [Abstract][Full Text] [Related]
27. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Haugh AM; Salama AKS; Johnson DB
Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
[TBL] [Abstract][Full Text] [Related]
28. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
30. The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations.
Berger M; Richtig G; Kashofer K; Aigelsreiter A; Richtig E
G Ital Dermatol Venereol; 2018 Jun; 153(3):349-360. PubMed ID: 29600692
[TBL] [Abstract][Full Text] [Related]
31. Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.
Griewank KG; Schilling B
Am J Clin Dermatol; 2017 Jun; 18(3):303-310. PubMed ID: 28229402
[TBL] [Abstract][Full Text] [Related]
32. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C; Hassel JC
Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
[TBL] [Abstract][Full Text] [Related]
33. The future of targeted kinase inhibitors in melanoma.
Caksa S; Baqai U; Aplin AE
Pharmacol Ther; 2022 Nov; 239():108200. PubMed ID: 35513054
[TBL] [Abstract][Full Text] [Related]
34. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
[TBL] [Abstract][Full Text] [Related]
35. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?
Moreno-Ramírez D; Fernández-Orland A; Ferrándiz L
Actas Dermosifiliogr; 2024 Jan; 115(1):48-55. PubMed ID: 37321549
[TBL] [Abstract][Full Text] [Related]
37. The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck.
Wilson MA; Fecher LA
Otolaryngol Clin North Am; 2021 Apr; 54(2):329-342. PubMed ID: 33602512
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
39. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
[TBL] [Abstract][Full Text] [Related]
40. Universes collide: combining immunotherapy with targeted therapy for cancer.
Wargo JA; Cooper ZA; Flaherty KT
Cancer Discov; 2014 Dec; 4(12):1377-86. PubMed ID: 25395294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
